A Trial of Sintilimab Plus Anlotinib For Metastatic NSCLC After First-Line PD-1 Inhibitor

Summary

The combination of immunocheckpoint inhibitors and anti-angiogenesis therapy has synergistic anti-tumor effect and is a reasonable method to improve the prognosis of patients. Therefore, in this study, it is hoped that sintilimab combined with anlotinib can overcome immunotherapy resistance, improve the efficacy of immunotherapy, and further improve the survival of patients, so as to provide more clinical evidence for the treatment of advanced NSCLC patients with negative driver gene after first-line treatment with anti-PD-1 antibody.

Timeline

Start

2021-03-01

Primary completion

2024-09-04

Completion

2024-12-01

Publications

• Shi X, Lin C, Lou L, He Q, Lou G, Hong W, Shao L, Zhao J, Gu C, Yu X, Jin Y. An Open-Label, Single-Arm, Phase II Trial of Sintilimab Plus Anlotinib for Metastatic Non-Small Cell Lung Cancer After First-Line PD-(L)1 Inhibitor. Cancer Med. 2025 Sep;14(17):e71191. doi: 10.1002/cam4.71191.

Drugs

Indications